Clin2
NCT05801380Possibly a fitRecruiting

Tracking how well a medicine works in Alzheimer’s patients

Alzheimer Disease

Part of Brain & nervous system, Mental health clinical trials.

This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
60 people
Ages
65 years and older
Study type
Observational

Who can take part

  • Be age 65 or older
  • Have a new diagnosis of mild or moderate dementia from Alzheimer’s
  • Have not started Alzheimer’s memory medicines yet (or stopped within the last 3 months only because of side effects)
  • Live in the National Capital Region and be able to read and understand English and Filipino
  • Have a brain CT scan that does not suggest other main causes of dementia (except for small “lacunes,” 2 or fewer)
  • Be free of certain stomach and bowel issues and avoid certain medicines/foods around the time of stool sample collection

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03454646Not yet recruiting· Phase 4
Alzheimer care comparison using dementia medicines

This study compares different treatment strategies for people newly diagnosed with Alzheimer disease using cholinesterase inhibitor medicines. It may help show which approach works best for mild to moderate Alzheimer symptoms and how well people can stay stable over time.

Amiens
NCT06481878Recruiting
Testing a stool test for Alzheimer’s markers

This study checks if Alzheimer’s-related proteins (amyloid and tau) can be found in stool samples. It may help develop a simple, non-invasive way to detect Alzheimer’s disease.

Grenoble
NCT06995573Recruiting· Phase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness

This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.

Salzburg, State of Salzburg
NCT07062198Recruiting· Phase 3
Metabolic supplement for Alzheimer's disease

This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.

Alanya
NCT07058688Recruiting· Phase 2
Testing a new drug for Alzheimer's (NTRX-07)

This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.

Brno
NCT05183321Not yet recruiting
Drug treatment for gum disease in people with Alzheimer’s

This trial studies whether treating periodontal (gum) disease can help people who have probable Alzheimer’s disease. You may take a study treatment and have regular checks by a caregiver and study team.

Hear when a new Alzheimer Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.